# Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

> **NCT05297994** · PHASE2 · COMPLETED · sponsor: **St. Petersburg Research Institute of Vaccines and Sera** · enrollment: 400 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Flu-M [Inactivated split influenza vaccine]
- **BIOLOGICAL:** Inactivated influenza split vaccine

## Key facts

- **NCT ID:** NCT05297994
- **Lead sponsor:** St. Petersburg Research Institute of Vaccines and Sera
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-24
- **Primary completion:** 2016-12-12
- **Final completion:** 2017-03-09
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05297994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05297994, "Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05297994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*